Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA
Clinical and Experimental Nephrology · 2024
DOI: 10.1007/s10157-024-02483-w ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Experimental Nephrology, 2024. Verfasst von Tetsuya Yamamoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gyoumeikan Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Hyperuricemia, Renal Insufficiency, Chronic, Uric Acid, Albuminuria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fuji Pharma.
Abstract (Originalsprache)
Background
We investigate whether Intensive uric acid (UA)-lowering therapy (ULT) provides increased renal protection compared with standard therapy in chronic kidney disease (CKD) patients.
Methods
This was a multicenter randomized controlled trial. Only CKD patients with hyperuricemia were included in this study. The participants were randomly assigned to either the Intensive therapy group (target serum UA level ≥ 4.0 mg/dL and < 5.0 mg/dL) or the standard therapy group (serum UA level ≥ 6.0 mg/dL and < 7.0 mg/dL). ULT was performed using topiroxostat, a non-purine-type selective xanthine oxidase inhibitor. The primary endpoint was change in the logarithmic value of urine albumin to the creatinine ratio (ACR) between baseline and week 52 of the treatment.
Results
Three hundred fifty-two patients were included in the full analysis set. In the Standard therapy group, mean serum UA was 8.23 mg/dL at baseline and 6.13 mg/dL at 52 weeks. In the Intensive therapy group, mean serum UA was 8.15 mg/dL at baseline and 5.25 mg/dL at 52 weeks. There was no significant difference in changes in log ACR at 52 weeks between the Intensive therapy and the Standard therapy groups.
Conclusion
This study did not reveal the benefit of Intensive ULT to improve albuminuria levels. (UMIN000026741 and jRCTs051180146).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gyoumeikan Hospital, Osaka, Japan.
- Nara Medical University, Kashihara, Japan. kasa@naramed-u.ac.jp.
- Ujitakeda Hospital, Uji, Japan.
- Kawasaki Medical School, Okayama, Japan.
- JCHO Tokyo Takanawa Hospital, Tokyo, Japan.
- Yamagata University, Yamagata, Japan.
Förderung
- Fuji Pharma
Zitieren
APA
Yamamoto, T., Kasahara, M., Ueshima, K., Uemura, S., Kashihara, N., Kimura, K., Konta, T., Shoji, T., Mima, A., Mukoyama, M., & Saito, Y. (2024). Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02483-w
Vancouver
Yamamoto T, Kasahara M, Ueshima K, Uemura S, Kashihara N, Kimura K, et al. Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA. Clinical and Experimental Nephrology. 2024. doi:10.1007/s10157-024-02483-w
BibTeX
@article{Yamamoto2024,
author = {Yamamoto, Tetsuya and Kasahara, Masato and Ueshima, Kenji and Uemura, Shiro and Kashihara, Naoki and Kimura, Kenjiro and Konta, Tsuneo and Shoji, Tetsuo and Mima, Akira and Mukoyama, Masashi and Saito, Yoshihiko},
title = {Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA},
journal = {Clinical and Experimental Nephrology},
year = {2024},
doi = {10.1007/s10157-024-02483-w}
}
EUVIMED